Menu
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.

Search results

Netflix vs. Roku: Which Streaming Stock is the Better Buy-the-Dip Target?: https://staticx-tuner.zacks.com/images/default_article_images/default159.jpg
Netflix vs. Roku: Which Streaming Stock is the Better Buy-the-Dip Target?

Two appealing buy-the-dip prospects that investors may be taking notice of are streaming services leaders Netflix NFLX and Roku ROKU.

Notably, Netflix stock has fallen 30% to under $80 a share since

Can Nebius Reach $7-$9B Annualized Run-Rate Revenue in 2026?
Can Nebius Reach $7-$9B Annualized Run-Rate Revenue in 2026?

Nebius Group N.V. NBIS has outlined an ambitious yet clearly defined financial trajectory, targeting an annualized run rate (ARR) revenue of between $7 billion and $9 billion by the end of 2026. The

Wall Street Analysts See a 57.03% Upside in LiveRamp (RAMP): Can the Stock Really Move This High?
Wall Street Analysts See a 57.03% Upside in LiveRamp (RAMP): Can the Stock Really Move This High?

Shares of LiveRamp (RAMP) have gained 0.4% over the past four weeks to close the last trading session at $25.11, but there could still be a solid upside left in the stock if short-term price targets

Wall Street Analysts Predict a 121.15% Upside in LiveOne (LVO): Here's  What You Should Know
Wall Street Analysts Predict a 121.15% Upside in LiveOne (LVO): Here's What You Should Know

LiveOne (LVO) closed the last trading session at $5.2, gaining 21.5% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set by Wall Street

Pfizer Targets Long-Term Oncology Growth Amid Competitive Pressure
Pfizer Targets Long-Term Oncology Growth Amid Competitive Pressure

Pfizer PFE is one of the largest and most successful drugmakers in oncology with an established presence in breast, genitourinary, thoracic, gastrointestinal cancer and blood cancers. It boasts a

Wall Street Analysts Think EuroDry (EDRY) Could Surge 35.09%: Read This Before Placing a Bet
Wall Street Analysts Think EuroDry (EDRY) Could Surge 35.09%: Read This Before Placing a Bet

Shares of EuroDry (EDRY) have gained 27.6% over the past four weeks to close the last trading session at $16.9, but there could still be a solid upside left in the stock if short-term price targets

Wall Street Analysts Think Insmed (INSM) Could Surge 33.6%: Read This Before Placing a Bet
Wall Street Analysts Think Insmed (INSM) Could Surge 33.6%: Read This Before Placing a Bet

Insmed (INSM) closed the last trading session at $161, gaining 0.4% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set by Wall Street

Wall Street Analysts See a 29.32% Upside in Copa Holdings (CPA): Can the Stock Really Move This High?
Wall Street Analysts See a 29.32% Upside in Copa Holdings (CPA): Can the Stock Really Move This High?

Copa Holdings (CPA) closed the last trading session at $139.34, gaining 4.4% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set by Wall

Wall Street Analysts Predict a 27.09% Upside in Brookdale (BKD): Here's  What You Should Know
Wall Street Analysts Predict a 27.09% Upside in Brookdale (BKD): Here's What You Should Know

Brookdale Senior Living (BKD) closed the last trading session at $14.95, gaining 17.4% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set

Can Boot Barn Reach Its 1,200 Store Potential Faster Than Expected?
Can Boot Barn Reach Its 1,200 Store Potential Faster Than Expected?

Boot Barn Holdings, Inc. BOOT maintains a long-term goal of reaching 1,200 locations across the United States and the feasibility of reaching the target ahead of schedule relies on store expansion

Wall Street Analysts Think Calix (CALX) Could Surge 34.87%: Read This Before Placing a Bet
Wall Street Analysts Think Calix (CALX) Could Surge 34.87%: Read This Before Placing a Bet

Calix (CALX) closed the last trading session at $55.61, gaining 2.6% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set by Wall Street

Quantum Outlook for March 2026: 3 Stocks With Over 100% Price Target
Quantum Outlook for March 2026: 3 Stocks With Over 100% Price Target

The quantum computing sector has recorded lackluster performance in February 2026. Month to date, the Defiance Quantum ETF QTUM has edged up 1.2% with many pure-plays showing volatility and

Dillard's (DDS) is a Top Buy the Dip Target Ahead of Q4 Earnings: https://staticx-tuner.zacks.com/images/articles/main/d9/2090.jpg
Dillard's (DDS) is a Top Buy the Dip Target Ahead of Q4 Earnings

In an earnings lineup that includes Q4 results from Nvidia NVDA, Dillard’s DDS will also be a stock to watch this week.

Dillard's unique business model, in which it owns most of its retail

SMR Targets 72 Modules With ENTRA1: Is Deployment on Track for 2030?
SMR Targets 72 Modules With ENTRA1: Is Deployment on Track for 2030?

NuScale Power SMR is planning a large nuclear deployment with its partner ENTRA1 Energy. This plan could reach up to 6 gigawatts (GW) of power capacity, equal to about 72 NuScale Power Modules

Zacks Investment Ideas feature highlights: Nvidia, Dillard's, Macy's and Kohl's
Zacks Investment Ideas feature highlights: Nvidia, Dillard's, Macy's and Kohl's

For Immediate Release

Chicago, IL – February 24, 2026 – Today, Zacks Investment Ideas feature highlights Nvidia NVDA, Dillard's DDS, Macy's M and Kohl's KSS.

Dillard's (DDS) a Top Buy-the-Dip Target

Does A10 Networks (ATEN) Have the Potential to Rally 28.83% as Wall Street Analysts Expect?
Does A10 Networks (ATEN) Have the Potential to Rally 28.83% as Wall Street Analysts Expect?

A10 Networks (ATEN) closed the last trading session at $18.94, gaining 6.3% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set by Wall

Wall Street Analysts Think SkyWest (SKYW) Could Surge 25.91%: Read This Before Placing a Bet
Wall Street Analysts Think SkyWest (SKYW) Could Surge 25.91%: Read This Before Placing a Bet

SkyWest (SKYW) closed the last trading session at $101.92, gaining 1.2% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set by Wall Street

Wall Street Analysts See a 28.32% Upside in Perrigo (PRGO): Can the Stock Really Move This High?
Wall Street Analysts See a 28.32% Upside in Perrigo (PRGO): Can the Stock Really Move This High?

Perrigo (PRGO) closed the last trading session at $14.55, gaining 1% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set by Wall Street

Wall Street Analysts Believe Nomad Foods (NOMD) Could Rally 30.26%: Here's is How to Trade
Wall Street Analysts Believe Nomad Foods (NOMD) Could Rally 30.26%: Here's is How to Trade

Nomad Foods (NOMD) closed the last trading session at $12.92, gaining 6.8% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set by Wall

4 GARP Stocks That Investors Can Scoop Up for Maximum Returns
4 GARP Stocks That Investors Can Scoop Up for Maximum Returns

Growth at a reasonable price, or GARP, is an excellent strategy to earn quick investment profits. The GARP approach helps identify stocks priced below the market or any suitable target determined by